Merck & Company Inc (MRK)vsTvardi Therapeutics, Inc. (TVRD)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
TVRD
Tvardi Therapeutics, Inc.
$3.15
+2.94%
HEALTHCARE · Cap: $30.02M
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
TVRD
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for TVRD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TVRD
The strongest argument for TVRD centers on Price/Book, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TVRD
The primary concerns for TVRD are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 26/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Tvardi Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering innovative therapies for oncology and other critical medical challenges. Utilizing its proprietary drug discovery platform, Tvardi focuses on the development of small molecule therapies that target protein degradation pathways to offer therapeutic advantages in cancer treatment. Its lead candidate, TVB-2640, is designed to undermine cancer cell survival mechanisms, showcasing the company's dedication to advancing treatment options for patients facing malignancies. With a strong pipeline and a commitment to scientific excellence, Tvardi is well-positioned to transform the cancer therapeutics arena and improve patient outcomes.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?